Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kortenberg – page 132

1 955 clinical trials in Kortenberg, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kortenberg at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Kortenberg

Open in trial search

Varices oesophageal+1

Not recruiting

Study on Belapectin for Preventing Esophageal Varices in Patients with NASH Cirrhosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galactoarabino-Rhamnogalacturonate
  • Sponsor:Galectin Therapeutics Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of BI 764198 for Patients with Focal Segmental Glomerulosclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim International GmbH

Neoplasm malignant

Not recruiting

A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GEN1047
  • Sponsor:Genmab A/S

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Hyperphagia

Not recruiting

Study on Carbetocin Nasal Spray for Reducing Uncontrollable Hunger in Patients with Prader-Willi Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Carbetocin
  • Sponsor:Acadia Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kortenberg

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The trials aim to evaluate alternative treatment approaches for managing functional dyspepsia and related conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options using alginate formulations, comparing their effectiveness with traditional tapering methods.

02 Digestive Health Studies

Clinical investigations examining treatment optimization for heartburn and reflux conditions. The research focuses on developing evidence-based approaches to reduce long-term medication dependency.

  • Symptom Management
  • Treatment Optimization
  • Medication Reduction Strategies

These trials aim to establish more effective approaches to managing digestive health while minimizing long-term medication use.

03 Primary Care Innovation

Primary care-focused research evaluating novel approaches to medication management in chronic conditions. The studies emphasize patient-centered strategies for reducing unnecessary long-term medication use.

  • Patient-Centered Care
  • Chronic Medicine Management
  • Evidence-Based Deprescribing

This research aims to transform primary care practices by establishing optimal deprescribing protocols for commonly used medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.